

Name of Journal: *World Journal of Gastroenterology*

Manuscript NO: 33335

Manuscript Type: ORIGINAL ARTICLE

Randomized Controlled Trial

New botanical drug, HL tablet, reduces hepatic fat as measured by magnetic resonance spectroscopy in patients with nonalcoholic fatty liver disease: A placebo-controlled, randomized, phase II trial

Jeong JY *et al.* HL tablet for nonalcoholic fatty liver disease

Jae Yoon Jeong, Joo Hyun Sohn, Yang Hyun Baek, Yong Kyun Cho, Yongsoo Kim and Hyeonjin Kim

Abstract

AIM

To evaluate the efficacy and safety of HL tablet extracted from *magnolia officinalis* for treating patients with nonalcoholic fatty liver disease (NAFLD).

Match Overview

1	Internet 95 words crawled on 15-Jun-2016 www.aasld.org	3%
2	Internet 31 words crawled on 29-May-2016 www.kasl.org	1%
3	Internet 21 words crawled on 08-Jan-2017 www.e-sciencecentral.org	1%
4	Crossref 18 words C. Stief "Sustained efficacy and tolerability with vardenafil ... over 2 years of treatment in men with erectile dysfunction", I	<1%
5	Internet 17 words crawled on 04-Dec-2015 www.science.gov	<1%
6	Crossref 14 words Firsching, Raimund, Jürgen Piek, Martin Skalej, Veit Rohde, Uwe Schmidt, and Frank Striggow. "Early Survival of Co	<1%
7	Internet 13 words crawled on 10-Jun-2017 www.accessdata.fda.gov	<1%
8	Internet 13 words crawled on 02-Aug-2014 www.letfreedomgrow.com	<1%

[全部](#)[新闻](#)[购物](#)[图片](#)[地图](#)[更多](#)[设置](#)[工具](#)

找到约 7,250 条结果 (用时 1.30 秒)

[PDF] Methods - AASLD

<https://www.aasld.org/sites/default/files/documents/2015/TLM.../LB32.pdf> ▼ [翻译此页](#)

TITLE: A new botanical drug, HL tablet, reduces significantly hepatic fat by ... nonalcoholic fatty liver disease: a placebo-controlled, randomized, Phase II clinical trial. ... randomized, double-masked, Phase II clinical trial: 74 patients with NAFLD ... variation of hepatic fat content by magnetic resonance spectroscopy (MRS).

Safety and Efficacy of HL Tablet in Non-alcoholic Fatty Liver Disease ...

<https://clinicaltrials.gov/ct2/show/NCT02491905> ▼ [翻译此页](#)

2015年6月24日 - Drug: HL tablet ... Official Title: Phase 2 Study to Assess Safety and Efficacy of HL Tablet on Reducing Hepatic Fat in Non-alcoholic Fatty Liver Disease Patients ... assess the change of hepatic fat by Magnetic Resonance spectroscopy (MRS) ... Placebo by oral administration, twice daily in an hour after meal.

Sitagliptin vs. placebo for nonalcoholic fatty liver disease: A ...

<https://www.ncbi.nlm.nih.gov/pubmed/27151177> - [翻译此页](#)

2016 May 2. pii: S0168-8278(16)30165-9. doi: 10.1016/j.jhep.2016.04.021. ... vs. placebo for nonalcoholic fatty liver disease: A randomized controlled trial. ... of a placebo in reducing liver fat measured by MRI-derived proton density-fat ... magnetic resonance elastography (MRE) and FIBROSpect® II to assess liver fibrosis.

Surveying the Latest Data in Fatty Liver Disease - Medscape

www.medscape.com/viewarticle/861129 ▼ [翻译此页](#)

ajor liver-related challenges that ... Recognition and

[全部](#)[图片](#)[新闻](#)[购物](#)[地图](#)[更多](#)[设置](#)[工具](#)

找到约 20,400 条结果（用时 0.72 秒）

[PDF] LB-32 A new botanical drug, HL tablet, reduces significantly hepatic f...

<https://www.aasld.org/sites/default/files/documents/2015/TLM.../LB32.pdf> - 翻译此页

TITLE: A new botanical drug, HL tablet, reduces significantly hepatic fat by ... nonalcoholic fatty liver disease: a placebo-controlled, randomized, Phase II clinical trial. ... randomized, double-masked, Phase II clinical trial: 74 patients with NAFLD ... variation of hepatic fat content by magnetic resonance spectroscopy (MRS).

Sitagliptin vs. placebo for nonalcoholic fatty liver disease: A ...

<https://www.ncbi.nlm.nih.gov/pubmed/27151177> - 翻译此页

2016 May 2. pii: S0168-8278(16)30165-9. doi: 10.1016/j.jhep.2016.04.021. ... vs. placebo for nonalcoholic fatty liver disease: A randomized controlled trial. ... of a placebo in reducing liver fat measured by MRI-derived proton density-fat ... magnetic resonance elastography (MRE) and FIBROSpect® II to assess liver fibrosis.

Ezetimibe for the Treatment of Nonalcoholic Steatohepatitis - NCBI - NIH

<https://www.ncbi.nlm.nih.gov> > NCBI > Literature > PubMed Central (PMC) - 翻译此页

作者: R Loomba - 2015 - 被引用次数: 69 - 相关文章

2015年2月27日 - Ezetimibe treatment improved diet-induced hepatic steatosis and fibrosis and ... features of NASH. Therefore, randomized, placebo-controlled trials are ... efficacy of ezetimibe versus placebo at reducing liver fat as measured by an ... patients underwent MRI, magnetic resonance spectroscopy (MRS, as an ...

Late - breaking abstracts - Wiley Online Library

<onlinelibrary.wiley.com/doi/10.1002/hep.28313/pdf> - 翻译此页

A Phase 3 Double-Blind Placebo-Controlled Evaluation of Sofosbuvir/Velpatasvir ... Methods: Patients with genotype 1, 2, 4, or 6 chronic HCV infection were ...

Acute and Chronic Complications - American Diabetes Association

diabetes.diabetesjournals.org/content/diabetes/65/Supplement_1/A101.full.pdf

作者: American Diabetes Association - 2016

QTc during Severe Hypoglycemia in Patients with Type 2 Diabetes. SEON AH CHA Fat Content

New botanical drug, HL tablet, reduces hepatic fat as measured by magnetic res

全部 图片 视频 新闻 地图 图书

找到约 21,100 条结果

时间不限

过去 1 小时内
过去 24 小时内
过去 1 周内
过去 1 个月内
过去 1 年内

所有结果

精确匹配

[\[PDF\] LB-32 A new botanical drug, HL tablet, reduces significantly hepatic ...](#)

<https://www.aasld.org/sites/default/files/documents/.../LB32.pdf>

TITLE: A new botanical drug, HL tablet, reduces significantly hepatic fat by ... nonalcoholic fatty liver disease: a placebo-controlled, randomized, Phase II clinical trial ... randomized, double-masked, Phase II clinical trial: 74 patients with NAFLD ... variation of hepatic fat content by magnetic resonance spectroscopy (MRS).

[Sitagliptin vs. placebo for nonalcoholic fatty liver disease: A ...](#)

<https://www.ncbi.nlm.nih.gov/pubmed/27151177>

2016 May 2. pii: S0168-8278(16)30165-9. doi: 10.1016/j.jhep.2016.04.021. ... vs. placebo for nonalcoholic fatty liver disease: A randomized controlled trial. ... of a placebo in reducing liver fat measured by MRI-derived proton density-fat ... magnetic resonance elastography (MRE) and FIBROSpect® II to assess liver fibrosis.

[Ezetimibe for the Treatment of Nonalcoholic Steatohepatitis ...](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4407930/>

27 Feb 2015 ... Ezetimibe treatment improved diet-induced hepatic steatosis and fibrosis and ... features of NASH. Therefore, randomized, placebo-controlled trials are ... efficacy of ezetimibe versus placebo at reducing liver fat as measured by an ... patients underwent MRI, magnetic resonance spectroscopy (MRS, as an ...

[\[PDF\] Late – breaking abstracts - Wiley Online Library](#)

<onlinelibrary.wiley.com/doi/10.1002/hep.28313/pdf>

A Phase 3 Double-Blind Placebo-Controlled Evaluation of Sofosbuvir/Velpatasvir ... Methods: Patients with genotype 1, 2, 4, or 6 chronic HCV infection were ...

[\[PDF\] Acute and Chronic Complications - American Diabetes Association](#)

<diabetes.diabetesjournals.org/content/diabetes/65/...1/A101.full.pdf>

QTc during Severe Hypoglycemia in Patients with Type 2 Diabetes SEON AH CHA Fat